Chimeric trnalys-ribozyme molecules
CA 2114312 A1 · Owner: Larson, Garry P. · Inventors: Larson, Garry P.; Rossi, John J.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention provides novel chimeric tRNALYS-ribozyme molecules that compete effectively with tRNALYS for HIV-1 reverse transcriptase binding sites. The chimeric human tRNALYS-ribozymes inhibit reverse HIV transcription by delivering inhibitors such as ribozymes of HIV-1 reverse transcriptase directly to the virion particle and render it non-functional. The chimeric molecules of the invention thus serve as highly specific non-toxic therapeutic agents. These chimeric molecules also reveal a novel site, specific RNA cleaving activity of HIV-1.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 27, 1992. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended May 27, 2012.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 27, 2014.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.